Law360, San Diego (December 09, 2011, 10:16 PM ET) -- A unit of Valeant Pharmaceuticals International Inc. on Thursday resolved its suit in New York federal court accusing Par Pharmaceutical Cos. Inc. of infringing its patents by seeking to launch a generic version of Valeant’s antidepressant Aplenzin.
U.S. District Judge Richard Berman signed off on the parties’ bid to dismiss their claims against each other with prejudice after Par stipulated that the proposed generic drug would infringe Valeant International (Barbados) SRL’s patents-in-suit.
The parties agreed to cover their own attorneys’ fees and costs. Attorneys representing Valeant...
Valeant Ends Fight With Par Over Generic Antidepressant
To view the full article, take a free trial now.
